​

1. Montague ECoulter, Ozcan B, Sefton E, Wulkan F, Alibhai FJ, Laflamme MA. Human pluripotent stem cell-based cardiac repair: Lessons learned and challenges ahead. Advanced Drug Delivery Reviews. 2025;222:115594. doi:https://doi.org/10.1016/j.addr.2025.115594

 

2. Chow M, Boheler KR, Li RA. Human pluripotent stem cell-derived cardiomyocytes for heart regeneration, drug discovery and disease modeling: from the genetic, epigenetic, and tissue modeling perspectives. Stem Cell Research & Therapy. 2013;4(4):97. doi:https://doi.org/10.1186/scrt308

 

3.Bain JD, Barrs RW, Mei Y. Progress and challenges in transplantation of human pluripotent stem cell derived cardiomyocytes for cardiac therapy. npj Biomedical Innovations. 2026;3(1). doi:https://doi.org/10.1038/s44385-025-00048-4

 

4.Brandão KO, Tabel VA, Atsma DE, Mummery CL, Davis RP. Human pluripotent stem cell models of cardiac disease: from mechanisms to therapies. Disease Models & Mechanisms. 2017;10(9):1039-1059. doi:https://doi.org/10.1242/dmm.030320

 

5.Shahannaz DC, Sugiura T, Ferrell BE, Yoshida T. Arrhythmogenic Risk in iPSC-Derived Cardiomyocytes: Current Limitations and Therapeutic Perspectives. Medicina. 2025;61(11):2056. doi:https://doi.org/10.3390/medicina61112056

 

6.Wulkan F, Romagnuolo R, Qiang B, et al. Stem cell-derived cardiomyocytes expressing a dominant negative pacemaker HCN4 channel do not reduce the risk of graft-related arrhythmias. Frontiers in cardiovascular medicine. 2024;11:1374881. doi:https://doi.org/10.3389/fcvm.2024.1374881

 

7.Chen JX, Krane M, Deutsch MA, et al. Inefficient reprogramming of fibroblasts into cardiomyocytes using Gata4, Mef2c, and Tbx5. Circulation Research. 2012;111(1):50-55. doi:https://doi.org/10.1161/CIRCRESAHA.112.270264

 

8.Zhao Y, Londono P, Cao Y, et al. High-efficiency reprogramming of fibroblasts into cardiomyocytes requires suppression of pro-fibrotic signalling. Nature Communications. 2015;6(1). doi:https://doi.org/10.1038/ncomms9243

 

9.Ieda M, Fu JD, Delgado-Olguin P, et al. Direct Reprogramming of Fibroblasts into Functional Cardiomyocytes by Defined Factors. Cell. 2010;142(3):375-386. doi:https://doi.org/10.1016/j.cell.2010.07.002

 

10.UNIVERSITY of CALIFORNIA, MERCED towards the Fabrication of Three-Dimensional Cardiac Tissue Derived from Stem Cells.; 2019. Accessed February 9, 2026. https://escholarship.org/content/qt4ch6v1q0/qt4ch6v1q0_noSplash_742785a7c9476a6c0626812439d2a613.pdf?

 

11.Weintraub WS, Taggart DP, Mancini GBJ, Brown DL, Boden WE. Historical Milestones in the Management of Stable Coronary Artery Disease over the Last Half Century. American Journal of Medicine. 2018;131(11):1285-1292. doi:https://doi.org/10.1016/j.amjmed.2018.05.039

 

12.History Center. Ptca.org. Published 2023. Accessed February 9, 2026. https://www.ptca.org/history_timeline.html?

 

13.Nabel E, Braunwald E. A Tale of Coronary Artery Disease and Myocardial Infarction. Accessed February 9, 2026. https://www.jvsmedicscorner.com/Medicine_files/A%20Tale%20of%20Coronary%20Artery%20Disease%20and%20Myocardial%20Infarction.pdf

 

14.de Oliveira Laterza Ribeiro M, Correia VM, Herling de Oliveira LL, Soares PR, Scudeler TL. Evolving Diagnostic and Management Advances in Coronary Heart Disease. Life. 2023;13(4):951. doi:https://doi.org/10.3390/life13040951

 

15.Sun B, Wang L, Guo W, Chen S, Ma Y, Wang D. New treatment methods for myocardial infarction. Frontiers in Cardiovascular Medicine. 2023;10. doi:https://doi.org/10.3389/fcvm.2023.1251669

 

16.Liu P, Chen G, Zhang J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules. 2022;27(4). doi:https://doi.org/10.3390/molecules27041372

 

17.Pollard H. The legacy of liposomes: how fundamental research keeps on giving | Babraham Institute. Babraham.ac.uk. Published October 17, 2023. https://www.babraham.ac.uk/blog/legacy-of-liposomes

 

18.Qin Y, Ou L, Zha L, Zeng Y, Li L. Delivery of nucleic acids using nanomaterials. Molecular Biomedicine. 2023;4(1). doi:https://doi.org/10.1186/s43556-023-00160-0

 

19.Suzuki Y, Ishihara H. Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metabolism and Pharmacokinetics. 2021;41:100424. doi:https://doi.org/10.1016/j.dmpk.2021.100424

 

20.Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021;6(6):1078-1094. doi:https://doi.org/10.1038/s41578-021-00358-0

 

21.Lee A, Sousa de Almeida M, Milinkovic D, et al. Substrate stiffness reduces particle uptake by epithelial cells and macrophages in a size-dependent manner through mechanoregulation. Nanoscale. 2022;14(40):15141-15155. doi:https://doi.org/10.1039/d2nr03792k

 

22.Panciera T, Azzolin L, Cordenonsi M, Piccolo S. Mechanobiology of YAP and TAZ in physiology and disease. Nature Reviews Molecular Cell Biology. 2017;18(12):758-770. doi:https://doi.org/10.1038/nrm.2017.87

 

23.Battilana G, Zanconato F, Piccolo S. Mechanisms of YAP/TAZ transcriptional control. Cell Stress. 2021;5(11):167-172. doi:https://doi.org/10.15698/cst2021.11.258

 

24.Farbehi N, Patrick R, Aude Dorison, et al. Single-cell expression profiling reveals dynamic flux of cardiac stromal, vascular and immune cells in health and injury. eLife. 2019;8. doi:https://doi.org/10.7554/elife.43882

 

25.Rog-Zielinska EA, Norris RA, Kohl P, Markwald R. The Living Scar – Cardiac Fibroblasts and the Injured Heart. Trends in Molecular Medicine. 2016;22(2):99-114. doi:https://doi.org/10.1016/j.molmed.2015.12.006

 

26.Parrett BJ, Yamaoka S, Barry MA. Reducing off-target expression of mRNA therapeutics and vaccines in the liver with microRNA binding sites. Molecular Therapy Methods & Clinical Development. 2025;33(1):101402. doi:https://doi.org/10.1016/j.omtm.2024.101402

 

27.Bann GG, Dos Santos M, Chen K, et al. Cellular Reprogramming by PHF7 Enhances Cardiac Function Following Myocardial Infarction. Circulation. 2025;152(9):616-629. doi:https://doi.org/10.1161/circulationaha.124.072733

 

28.Europe PMC. Europe PMC. Europepmc.org. Published 2016. Accessed February 9, 2026. https://europepmc.org/article/PMC/PMC8243412

 

29.Kaelin WG, Ratcliffe PJ. Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway. Molecular Cell. 2008;30(4):393-402. doi:https://doi.org/10.1016/j.molcel.2008.04.009

 

30.Zhao Xinxin, Pan H, Qiao L. Research progress of connexin 43 in cardiovascular diseases. Frontiers in Cardiovascular Medicine. 2025;12. doi:https://doi.org/10.3389/fcvm.2025.1650548

 

31.Greener ID, Sasano T, Wan X, et al. Connexin43 Gene Transfer Reduces Ventricular Tachycardia Susceptibility After Myocardial Infarction. Journal of the American College of Cardiology. 2012;60(12):1103-1110. doi:https://doi.org/10.1016/j.jacc.2012.04.042

 

32.Marino M, Scuderi F, Provenzano C, Bartoccioni E. Skeletal muscle cells: from local inflammatory response to active immunity. Gene Therapy. 2010;18(2):109-116. doi:https://doi.org/10.1038/gt.2010.124

 

33.Purohit MP, Yu BJ, Roy KS, et al. Acoustically activatable liposomes as a translational nanotechnology for site-targeted drug delivery and noninvasive neuromodulation. Nature Nanotechnology. Published online August 18, 2025:1-12. doi:https://doi.org/10.1038/s41565-025-01990-5

 

34.Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1  is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proceedings of the National Academy of Sciences. 1998;95(14):7987-7992. doi:https://doi.org/10.1073/pnas.95.14.7987

 

35.Lapteva L, Purohit-Sheth T, Serabian M, Puri RK. Clinical Development of Gene Therapies: The First Three Decades and Counting. Molecular Therapy - Methods & Clinical Development. 2020;19:387-397. doi:https://doi.org/10.1016/j.omtm.2020.10.004

 

36.National Human Genome Research Institute. What Are the Ethical Concerns of Genome Editing? National Human Genome Research Institute. Published August 3, 2017. https://www.genome.gov/about-genomics/policy-issues/Genome-Editing/ethical-concerns

 

37.MedlinePlus. Is gene therapy safe? medlineplus.gov. Published February 28, 2022. https://medlineplus.gov/genetics/understanding/therapy/safety/

 

38.Jessup M, Greenberg B, Mancini D, et al. Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID). Circulation. 2011;124(3):304-313. doi:https://doi.org/10.1161/circulationaha.111.022889

 

39.Centers for Disease Control and Prevention. Fast Facts: Health and Economic Costs of Chronic Conditions. Chronic Disease. Published July 12, 2024. https://www.cdc.gov/chronic-disease/data-research/facts-stats/index.html

 

40.Wiens KE, Xu H, Zou K, et al. Estimating the proportion of clinically suspected cholera cases that are true Vibrio cholerae infections: A systematic review and meta-analysis. PLoS medicine. 2023;20(9):e1004286-e1004286. doi:https://doi.org/10.1371/journal.pmed.1004286

 

41.Kim YH, Park DW, Song KY, Lim HG, Jeong JP, Kim JH. Use of High-Resolution Ultrasound in Characterizing the Surface Topography of a Breast Implant. Medicina. 2023;59(6):1092-1092. doi:https://doi.org/10.3390/medicina59061092

 

Web Page Image Citations:

Sanchez-Blanco A. Muscle Tissue after a Heart Attack.; 2025. Accessed February 9, 2026. https://www.instagram.com/p/DIxPp3Vs5x9/?img_index=3

 

Emergency Physicians. Heart Attack. Accessed February 9, 2026. https://www.emergencyphysicians.org/article/know-when-to-go/heart-attack

/

"Angioplasty Procedure - Uses, Indications, Surgery & Cost." PACE Hospitals, www.pacehospital.com/angioplasty-procedure.

​

"Arrhythmia." New York Cardiac & Diagnostic Center, newyorkcardiac.com/arrhythmia.

​

"Coronary Artery Bypass Surgery." Wikimedia Commons, commons.wikimedia.org/wiki/File:Coronary_Artery_Bypass_Surgery.jpg.

​

"Complete Guide to Understanding Lipid Nanoparticles (LNP)." InsideTX, insidetx.com/resources/reviews/complete-guide-to-understanding-lipid-nanoparticles-lnp/.

​

"Electrical Conduction in the Heart." Osmosis, www.osmosis.org/video/Electrical_conduction_in_the_heart.

​

"Heart Conduction System." Cleveland Clinic, my.clevelandclinic.org/health/body/21648-heart-conduction-system.

​

Riechman, I., et al. "Direct Cardiac Reprogramming." International Journal of Molecular Sciences, vol. 21, no. 21, 2020, www.mdpi.com/1422-0067/21/21/7950.

​

"Types of Cardiac Fibrosis." ResearchGate, www.researchgate.net/figure/Types-of-cardiac-fibrosis-The-extracellular-matrix-in-the-healthy-heart-left-is-a_fig1_360413269.

​

"Willem Einthoven ECG." Wikimedia Commons, commons.wikimedia.org/wiki/File:Willem_Einthoven_ECG.jpg.

​

Lu, T. Y., & Yang, L. (2011). Uses of cardiomyocytes generated from induced pluripotent stem cells. Stem Cell Research & Therapy, 2(6), 44. https://doi.org/10.1186/scrt85